BamSEC and AlphaSense Join Forces
Learn More

Supernus Pharmaceuticals Inc. – Plans of Reorganization, Merger, Acquisition or Similar

NASDAQ: SUPN    
Share price (6/5/26): $44.75    
Market cap (6/5/26): $2.597 billion
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 38 pages Asset Purchase Agreement
12/34/56
EX-2.1
from SC TO-C 105 pages Agreement and Plan of Merger Among: Sage Therapeutics, Inc., a Delaware Corporation; Supernus Pharmaceuticals, Inc., a Delaware Corporation; and Saphire, Inc., a Delaware Corporation Dated as of June 13, 2025
12/34/56
EX-2.1
from 8-K 105 pages Agreement and Plan of Merger Among: Sage Therapeutics, Inc., a Delaware Corporation; Supernus Pharmaceuticals, Inc., a Delaware Corporation; and Saphire, Inc., a Delaware Corporation Dated as of June 13, 2025
12/34/56
EX-2.1
from 8-K 125 pages Agreement and Plan of Merger by and Among: Adamas Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc., and Supernus Reef, Inc. Dated as of October 10, 2021
12/34/56
EX-2.1
from 10-Q 123 pages Confidential Dated April 28, 2020 US Worldmeds Partners, LLC (On Behalf of the Company Group) and Supernus Pharmaceuticals, Inc. Sale and Purchase Agreement Relating to Uswm Enterprises, LLC
12/34/56
EX-2.1
from 10-Q 76 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. Agreement and Plan of Merger by and Among Supernus Pharmaceuticals, Inc. Supernus Merger Sub, Inc. Biscayne Neurotherapeutics, Inc. and Reich Consulting Group, Inc. (As the Securityholder Representative) September 12, 2018
12/34/56
EX-2
from SC 13D/A ~1 page Joint Filing Agreement
12/34/56
EX-2
from SC 13D/A 1 page The Undersigned Hereby Agree to the Joint Filing of the Amendment No. 1 to Schedule 13d to Which This Agreement Is Attached. Dated: September 11, 2014
12/34/56
EX-2
from SC 13D 1 page Joint Filing Agreement
12/34/56